4.7 Article

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Biochemistry & Molecular Biology

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction

David M. Kurtz et al.

Article Radiology, Nuclear Medicine & Medical Imaging

Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma

Mathieu Nessim Toledano et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)

Article Medicine, General & Internal

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

R. Marcus et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Radiology, Nuclear Medicine & Medical Imaging

Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL

N. George Mikhaeel et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)

Article Radiology, Nuclear Medicine & Medical Imaging

Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy

Emmanuel Itti et al.

JOURNAL OF NUCLEAR MEDICINE (2009)

Article Radiology, Nuclear Medicine & Medical Imaging

Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma:: SUV-based assessment versus visual analysis

Chieh Lin et al.

JOURNAL OF NUCLEAR MEDICINE (2007)

Article Medicine, General & Internal

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

B Coiffier et al.

NEW ENGLAND JOURNAL OF MEDICINE (2002)